Persica Strengthens PP353 Case in Vertebrogenic Back Pain
London, UK — September 4, 2026 Persica Pharmaceuticals Limited announced the publication of new antibiotic exposure-response analyses supporting the...
chronic low back pain
Advertisement
Mesoblast Completes Treatment in Phase 3 Low Back Pain Trial
New York, USA / Melbourne, Australia August 17, 2026: Mesoblast Limited has completed patient treatment in its pivotal Phase...
Persica Pharmaceuticals Presents New PP353 Data Supporting Non-Opioid Chronic Low Back Pain Treatment
London, UK – July 24, 2026 Persica Pharmaceuticals has presented new scientific analyses supporting the development of its investigational...
Mesoblast Completes Enrollment in Low Back Pain Trial
NEW YORK and MELBOURNE, July 13-14, 2026 Mesoblast Limited announced that it has achieved its target of treating at...
Vertanical’s Exilby Wins First European Approval for Chronic Pain
GRÄFELFING, Germany – June 9, 2026 VERTANICAL has achieved a major milestone in chronic pain treatment after receiving Germany’s...
Advertisements
Mesoblast Completes Enrollment in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, USA & MELBOURNE, Australia, April 28–29, 2026 Mesoblast Limited has announced that it has achieved the patient...
Advertisement
